Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$10.23 - $12.94 $59,334 - $75,052
-5,800 Reduced 26.36%
16,200 $170 Million
Q4 2023

Feb 14, 2024

BUY
$7.36 - $10.89 $161,920 - $239,580
22,000 New
22,000 $232 Million

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $623M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.